<DOC>
	<DOCNO>NCT00275106</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , prednisolone dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know whether prednisolone effective dexamethasone give together combination chemotherapy treat lymphoblastic lymphoma . PURPOSE : This phase III randomize clinical trial study prednisolone see well work compare dexamethasone give together combination chemotherapy treat young patient newly diagnose lymphoblastic lymphoma .</brief_summary>
	<brief_title>Prednisolone Dexamethasone Combined With Chemotherapy Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free survival young patient newly diagnose lymphoblastic lymphoma treat induction prednisolone v dexamethasone . - Compare safety standard maintenance treatment 18 month vs 24 month patient . Secondary - Determine prognostic factor highly predicative treatment failure patient treat regimen . OUTLINE : This randomize , multicenter study . - Cytoreductive prephase : All patient receive methotrexate intrathecally ( IT ) day 1 prednisolone IV orally 3 time daily day 1-7 . - Induction phase ( part 1 ) : Patients T-cell lymphoblastic lymphoma ( T-LBL ) randomize 1 2 induction treatment arm . Patients LBL unknown immunophenotype assign arm I . Patients precursor B-cell lymphoblastic lymphoma ( pB-LBL ) assign arm II . - Arm I ( T-LBL LBL unknown immunophenotype ) : Patients receive prednisolone IV orally 3 time daily day 8-28 ; vincristine IV daunorubicin hydrochloride IV 1 hour day 8 , 15 , 22 , 29 ; asparaginase IV 1 hour day 12 , 15 , 18 , 21 , 24 , 27 , 30 , 33 ; methotrexate IT day 12 33 ; Patients CNS involvement receive additional methotrexate IT day 18 27 . Patients proceed part 2 induction phase . - Arm II ( T-LBL pB-LBL ) : Patients receive dexamethasone IV orally 3 time daily day 8-28 . Patients also receive vincristine , daunorubicin hydrochloride , asparaginase , methotrexate arm I . Patients proceed part 2 induction phase . - Induction phase ( part 2 ) : Patients receive cyclophosphamide IV 1 hour day 36 64 ; cytarabine IV day 38-41 , 45-48 , 52-55 , 59-62 ; oral mercaptopurine day 36-63 ; methotrexate IT day 45 59 . Two week later , patient proceed protocol M. - Protocol M : Patients receive oral mercaptopurine daily day 1-56 high-dose methotrexate IV continuously 24 hour , methotrexate IT day 8 , 22 , 36 , 50 . Patients also receive leucovorin calcium IV 42 , 48 , 54 hour start high-dose methotrexate infusion . Patients stratify accord stage disease ( I II v III IV ) . Patients stage I II disease proceed directly maintenance therapy 2 week completion protocol M. Patients stage III IV disease proceed re-induction phase 2 week completion protocol M. - Re-induction phase : Patients receive dexamethasone IV orally 3 time daily day 1-21 ; vincristine IV doxorubicin hydrochloride IV 1 hour day 8 , 15 , 22 , 29 ; asparaginase IV 1 hour day 8 , 11 , 15 , 18 ; cyclophosphamide IV 1 hour day 36 ; cytarabine IV day 38-41 45-48 ; oral thioguanine day 36-49 ; methotrexate IT day 38 45 . Patients proceed maintenance therapy 2 week completion re-induction phase . - Maintenance therapy : Patients T-LBL randomize 1 2 maintenance treatment arm . Patients pB-LBL LBL unknown immunophenotype assign arm I . Any patient evidence initial CNS involvement undergo cranial radiotherapy start maintenance therapy . Patients must show evidence progressive disease start maintenance therapy . - Arm I : Patients receive oral mercaptopurine day oral methotrexate week 2 year ( first day cytoreductive phase ) absence disease progression unacceptable toxicity . - Arm II : Patients receive treatment arm I 1Â½ year ( first day cytoreductive phase ) absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : Approximately 600 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm lymphoblastic lymphoma ( LBL ) Stage IIV disease Tcell LBL , precursor Bcell LBL , LBL unknown immunophenotype PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No known HIV AIDS infection No severe immunodeficiency No prior malignancy No prior disease would preclude treatment chemotherapy PRIOR CONCURRENT THERAPY : More 2 month since prior systemic corticosteroid duration &gt; 8 day No prior chemotherapy No prior radiotherapy No prior organ transplant No trimethoprimsulfamethoxazole 6 day methotrexate therapy No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
</DOC>